Wasatch Pharmaceutical, Inc., a development stage company, engages in the development of technology for the treatment of skin disorders that include acne, eczema, and psoriasis in the United States. The company is headquartered in Addison, Illinois.
| Revenue (TTM) | 810,220 |
| Gross Profit (TTM) | $-2.85M |
| EBITDA | $-9.99M |
| Operating Margin | -1233.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.11 |
| Book Value | $0.62 |
| Price-to-Book | 12.29 |
| Price-to-Sales (TTM) | 75.64 |
| EV/Revenue | 63.82 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -63.20% |
| Shares Outstanding | $10.94M |
| Float | $1.33M |
| % Insiders | 87.75% |
| % Institutions | 0.04% |